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Volatile organic compounds (VOCs) are produced by the human metabolism, inflammation and gut micro-
biota and form the basis of innovative volatomics research. VOCs detected through breath and faecal analysis
hence serve as attractive, non-invasive biomarkers for diagnosing and monitoring irritable bowel syndrome
(IBS) and inflammatory bowel disease (IBD). This review describes the clinical applicability of volatomics in
discriminating between IBS, IBD and healthy volunteers with acceptable accuracy in breath (70%-100%) and
faecal (58%-85%) samples. Promising compounds are propan-1-ol for diagnosing and monitoring of IBD
patients, and 1-methyl-4-propan-2-ylcyclohexa-1,4-diene as biomarker for IBS diagnosis. However, these
VOCs often seem to be related to inflammation and probably will need to be used in conjunction with other
clinical evidence. Furthermore, three interventional studies underlined the potential of VOCs in predicting
treatment outcome and patient follow-up. This shows great promise for future use of VOCs as non-invasive
breath and faecal biomarkers in personalised medicine. However, properly designed studies that correlate
VOCs to IBD/IBS pathogenesis, while taking microbial influences into account, are still key before clinical
implementation can be expected.
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Patients presenting with chronic abdominal pain and changes in
stool pattern are subjected to invasive procedures to differentiate
between irritable bowel syndrome (IBS), inflammatory bowel disease
(IBD), coeliac disease and colon cancer. The most prevalent of
these diseases is IBS with 11% [1], followed by colon cancer (8%) [2],
coeliac disease (1%) [3] and IBD (0.3%) [4]. Particularly, the differential
diagnosis between IBS and IBD is challenging, since both can present
similarly, especially when IBD is in remission [5,6].
IBS is characterised by abdominal pain and altered bowel habits in
the absence of organic disease of the gastrointestinal tract. Its aetiol-
ogy remains unknown, although patients often report an infectious,
traumatic or stressful event preceding the onset of symptoms. The
pathogenic mechanisms are most likely multifactorial, including
increased intestinal permeability, dysmotility, intestinal dysbiosis,food hypersensitivity, visceral hypersensitivity, brain-gut axis dysre-
gulation, inflammation, genetics, and psychological stress [7,8]. IBS has
a major impact on quality of life and is responsible for high healthcare
costs [9]. Four IBS subtypes are described according to the dominant
stool pattern and based on the Rome criteria: diarrhoea (IBS-D), consti-
pation (IBS-C), mixed (IBS-M) and unspecified (IBS-U) [10].
IBD encloses ulcerative colitis (UC) and Crohn’s disease (CD), both
having their own distinct pathological and clinical characteristics.
Approximately 253 million people in Europe suffer from IBD [11]
and they have up to 18% increased risk of developing colon cancer
[12]. IBD is caused by a chronically relapsing and uncontrolled intes-
tinal inflammation which can be difficult to manage [13]. IBD treat-
ment focuses on immune suppression, which is associated with side
effects (bone marrow suppression, infections) and a low response
rate [14]. People with suspected IBD are screened for flares and
inflammation by measuring faecal calprotectin, a marker for intesti-
nal neutrophilic inflammation. However, calprotectin is a non-spe-
cific inflammatory marker (sensitivity 83100%, specificity
60100%,) [15], and the definitive diagnosis is made on biopsies col-
lected through colonoscopy, which carries a risk of pain, bleeding
and perforation [16].
In IBS and IBD, there is a rising interest in the role of the micro-
biota, which influences intestinal physiology, nutrient absorption,
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healthy microbiota is characterised by a high individual diversity and
stability over time. However, a high interindividual variability exists
[17]. Several gastrointestinal diseases are associated with dysbiosis, a
reduction of this diversity and stability [17,18]. Microbiota composi-
tion is closely related to stool consistency [19] and is heavily influ-
enced by exogenous factors like antibiotics and food [17].
Non-invasive disease diagnosis and monitoring are the ‘Holy Grail’
for clinicians. Thirty-three to 57% of IBD patients in remission have
motility and/or sensitivity disturbances resembling IBS [6], challeng-
ing their differential diagnosis. There is an urgent need to develop
non-invasive, biomarkers that facilitate diagnosis and follow-up of
IBS and IBD patients. A new development in this area is volatomics
research, comprising volatile organic compounds (VOCs). VOCs have
a low molecular weight (<300 Da), a high vapour pressure at room
temperature [20] and are produced during physiological and patho-
logical metabolic processes (inflammation/oxidative stress) in the
human body [2123]. Furthermore, VOCs can also originate from
exogenous sources (food/drugs) and microbial metabolism [24,25]
and are excreted and detected via urine, skin, blood, faeces and
exhaled breath [26]. Two gasses are already used in clinical practice
to evaluate carbohydrate malabsorption and bacterial overgrowth in
breath analysis: methane (CH4) and hydrogen (H2) [2729].
Since IBD and IBS are both associated with (low-grade) inflamma-
tion and microbial changes, volatomics offer a non-invasive, tool to aid
in diagnosis, treatment and follow-up [21]. This review explores cur-
rent knowledge about using volatomics for (differential) diagnosis of
IBS and IBD, for discriminating between disease subtypes, phenotypes
and active and quiescent disease, to monitor treatment response and
to explore the effect of the microbiota on VOC composition.
2. Literature search
We used a systematic approach to search the literature concern-
ing VOCs in IBS and IBD. A full description of the search methods can
be found with supplementary Fig. 1. Articles studying methane or
hydrogen were excluded since recent reviews showed their potential
clinical use, albeit, with important limitations due to metabolic and
microbial variations [2729].
Quality of the articles was assessed with the AXIS quality appraisal
tool for cross-sectional research [30,31]. Twenty questions were eval-
uated by two independent assessors with a score of 1 for ‘yes’ and 0
for ‘no’/‘not applicable’/‘not reported’ as answer. Every study was
given a total score out of 20, with a higher score indicating a lower
risk of bias and, therefore, higher study quality. Initial assessment
gave an inter-assessor agreement of 971%. All studies lost approxi-
mately five points because relevant information was not mentioned,
or AXIS questions were not applicable to the research protocol. Con-
sensus was reached and the quality score per article ranged between
10 and 15 out of 20 with one study scoring 10 and one scoring 15.
Most studies scored 14 (46%) or 13 (21%) out of 20, indicating average
quality (supplementary Table 1).
Publication year, study (type, intervention), volatomic (source, ana-
lytical method) and population characteristics (IBS/IBD characteristics,
exclusion criteria, participant numbers, gender, race, smoking, BMI),
and results of interventions were catalogued. Study characteristics and
technical details can be found in Table 1. A more in-depth overview of
detection approaches can be found in Table 2.
Eight articles included IBS patients and defined their population
by the Rome criteria (three Rome II and two Rome III), the Manning
criteria (one), or did not specify the diagnostic criteria (two) (Table 1).
Next to fulfilling Rome criteria, diagnosis of IBS also requires absence
of organic disease, which was explicitly described by most articles.
Two studies only included IBS-D patients [32,33], one all IBS subtypes
[24], three multiple subtypes [3436] and two did not specify sub-
types (supplementary Table 2) [37,38]. The 17 studies including IBDpatients studied CD (n = 3), UC (n = 3) or both (n = 11). Five pooled CD
plus UC data in one IBD group for analysis [32,34,3941]. To assess
disease activity in IBD patients, the Harvey-Bradshaw index (HBI) for
CD and the Simple Clinical Colitis Activity Index (SCCAI) for UC were
predominantly used with the exception of one study using indium-
labelled granulocyte nuclear imaging [39].
The majority of studies did not report exclusion criteria. When
present, these included major comorbidities, organic disease in case
of IBS, major abdominal surgery, pregnancy and breast feeding. Nine
studies excluded patients with prior antibiotic use 2 to 12 weeks
before sampling [35,37,38,40,4246]. Other excluded drugs were
pro/prebiotics and drugs influencing the immune system and/or
microbiota.
Taking the abovementioned into account, the small number of
studies and large interstudy heterogeneity undermines a thorough
systematic analysis. Therefore, a narrative review is better suited to
discuss the results.
3. Results
3.1. Single VOCs for diagnosis and monitoring
Differentiating patients from healthy people allows the identifica-
tion of VOCs that represent a healthy volatilome. However, although
healthy volunteers (HV) are rarely seen in clinical practice, and,
hence, their discrimination has limited clinical utility, information
about their baseline volatilome will be of interest to assess whether
treatment of patients leads to normalisation of VOCs. More impor-
tantly, being able to differentiate between closely associated diseases
will be key. Supplementary Table 3 summarises all VOCs that signifi-
cantly differ between HV and IBS and IBD patients. Considering clini-
cal applicability, only compounds described in more than one study
are further discussed.
3.1.1. Inflammatory bowel disease
When comparing CD patients (active and remission pooled) to HV,
10 compounds were described in multiple studies (Fig. 1a). Six of
these compounds were described twice by the same research group,
mostly using the same or overlapping study populations [37,4648].
This includes pentane [47,48], which was confirmed by Pelli et al.,
looking only at active CD [49]. 2-methylbuta-1,3-diene [40,47] and
methylsulphanylmethane [40,44] were found increased in the breath
of CD patients and contradictory results have been found for breath
sulphane [44,47]. Propan-1-ol was increased in faeces and breath in
four studies including CD patients [32,37,46,47]. In active CD, 6-
methylheptan-2-one, heptanal and piperidin-2-one were found
increased in faecal samples in two studies of the same research group
[32,45]. No common compounds were found differentiating CD
patients in remission from HV, suggesting a normalisation of VOCs to
a baseline healthy volatilome. Two studies found an increase in
breath pentane in UC patients [47,48], which was confirmed by
another study in active UC patients [49].
3.1.2. Irritable bowel syndrome
Only one compound (1-methyl-4-propan-2-ylcyclohexa-1,4-
diene) was increased in faecal and breath samples (Fig. 1b) when
comparing IBS patients to HV [24,32].
3.1.3. Differential diagnosis
Regarding the use of individual VOCs for differential diagnosis,
four articles (two by one group) described an increase in propan-1-ol
in breath and faeces of CD patients compared to IBS-D patients, (sup-
plementary Table 3) [32,37,46,47]. When comparing UC to IBS-D and
IBS-D to general IBD patients, no compounds were identified in mul-
tiple studies. However, 1-methyl-4-propan-2-ylcyclohexa-1,4-diene
was only detected in IBS patients (breath and faeces).
Table 1
Study characteristics.




Processing and analytical information VOC identification* Validationy Comparison
IBD
Garner et al. [42] 2007 NA No Faeces GCMS Processing: Within 1 h. Storage: 20°C. Quantity: 24 g. Prepara-
tion: 60°C for 1 h. Headspace: Yes, SPME. GC column: SPB1
Capillary GC Column (L £ I.D.30m £ 025 mm, df 025mm;




UC and HV and
Clostridium
infection
Kumari et al. [43] 2013 SCCAI No Faeces GC Processing: Within 3 h. Storage: 80°C. Quantity: 250 -mg. Prepa-
ration: Supernatans development. Headspace: No. GCcolumn:
NA.
External standards NA UC and HV
Ahmed et al. [45] 2016 HBI, SCCAI No Faeces GCMS Processing: Within 6 h. Storage: 20°C. Quantity: 2 g. Prepara-
tion: 60°C for 1 h. Headspace: Yes, SPME.- GCcolumn: SPB1
Capillary GC Column (L £ I.D. 60 m £ 025 mm, df 025mm;
Supelco, Sigma Aldrich).
NIST NA UC and CD and HV
Kokoszka et al. [39] 1993 Indium-labelled
granulocyte
nuclear imaging
No Breath GC Processing: Haldane-Prestly tube -> plastic syringe. Storage: <
6 h. Quantity: 50 -ml. Preparation: NA. Headspace: NA. GCcol-
umn: NA.
NA NA IBD relapse and de
novo symptoms
Pelli et al. [49] 1999 HBI, SCCAI No Breath GC Collection: 1L Tedlar bag. Storage: NA. Quantity: 100 ml. Prepara-
tion: Adsorption -> thermal desorption -> concentration.
Headspace: NA.- GCcolumn: Al2O3/KCI column (25 m, 032ram,
05 mm; Chrompack).
NA NA UC and CD and HV
Dryahina
et al. [48]
2013 NA No Breath SIFT-MS Processing: NA. Storage: No. Quantity: 3 ex- and inhalations.
Preparation: NA. Headspace: NA. GC-column: NA.
Reagents NA UC and CD and HV
Bodelier et al. [53] 2015 HBI No Breath GCMS Processing: Within 2 h; 5L Tedlar bag -> stainless steel adsorption
tubes. Storage: Room temperature. Quantity: NA. Preparation:
NA. Headspace: NA. GC-column: NA.
NIST Trainingz CD and HV
Hicks et al. [44] 2015 HBI, SCCAI No Breath SIFT-MS Collection: 2L Nalophan bag. Storage: < 2 h. Quantity: 2L. Prepa-




UC and CD and HV
Arasaradnam
et al. [41]
2016 HBI, SCCAI No Breath FAIMS Collection: 3L Tedlar bag. Storage: 20°C for maximum 24 h.
Quantity: NA. Preparation: Room temperature for
1 h + transport time. Headspace: NA. GC-column: NA.
NA 10-fold CV UC and CD and HV
Rieder et al. [40] 2016 NA No Breath SIFT-MS Collection: Mylar bag. Storage: < 2 h. Quantity: NA. Preparation:
37°C for 10 min. Headspace: NA. GC-column: NA.
Reagents NA IBD and HV
Dryahina
et al. [47]
2017 HBI, SCCAI No Breath SIFT-MS,
GCMS
Collection: 3L Nalophan bag. Storage: 37°C for 510 min. Quan-
tity: NA. Preparation: 37°C. Headspace: NA. GC-column: NA.
Reagents NA UC and CD and HV
Smolinska
et al. [67]
2017 SCCAI No Breath GCMS Processing: Within 1 h; 5L Tedlar bag -> stainless steel adsorption
tube. Storage: Room temperature. Quantity: NA. Preparation:
NA. Headspace: NA. GC-column: NA.





2018 HBI No Breath GCMS Processing: Within 1 h; 5L Tedlar bag -> stainless steel adsorption
tube. Storage: Room temperature for maximum 2 weeks. Quan-
tity: NA. Preparation: Purged for 5 min. Headspace: NA. GC-col-
umn: RestekTM RTX-5 ms (30 m x 025 mm ID, coated with
10 mm HP-5 phase; Thermo Fisher Scientific)




2011 HBI, SSCAI No Urine E-nose, MS Processing: NA. Storage: NA. Quantity: 510 ml (E-nose), 1 ml
(MS). Preparation: 38°C for 1 h (E-nose), 60°C for 12 min (MS).
Headspace: Yes. GC-column: NA.
NA NA UC and CD and HV
Arasaradnam
et al. [66]
2013 NA No Urine E-nose, FAIMS Processing: Within 6 h. Storage: 20°C. Quantity: 2 g. Prepara-
tion: 60°C for 1 h. Headspace: Yes, SPME. GC-column: SPB1
NA NA UC and CD and HV

















Processing and analytical information VOC identification* Validationy Comparison
IBD




2016 HBI Yes Breath and
faeces
GCMS Processing: Within 4 h (faeces), Bio-VOC sampler -> TD tube
(breath). Storage: 80°C (faeces). Quantity: 5 ml (faeces). Prep-
aration: 37°C for 10 min (faeces), purged for 2 min -> desorp-
tion (breath). Headspace: Yes, 500 ml (faeces). GC-column:
ZebronTM ZB-624 GC Capillary Column (20 m x 018 mm x
100mm; Phenomenex).




Rossi et al. [35] 2017 Rome III Yes Faeces GC Processing: Within 1 h; Ice -> homogenised. Storage: 80°C.
Quantity: 750 mg. Preparation: 50°C for 10 min. Headspace:
Yes, 2 cm3. GC-column: SPB1 Capillary GC Column (L £ I.






2016 Rome III No Breath GCMS Processing: 3L Tedlar bag -> stainless steel adsorption tube. Stor-
age: Room temperature for maximum 28 weeks. Quantity:








2014 Rome II No Urine FAIMS, GCMS Processing: Within 2 h. Storage: 80°C. Quantity: 5 ml. Prepara-







Ahmed et al. [32] 2013 Manning,
HBI, SCCAI
No Faeces GCMS Processing: Within 6 h. Storage: 20°C. Quantity: 2 g. Prepara-
tion: 60°C for 1 h. Headspace: Yes, SPME. GC-column: SPB1






IBS and UC and CD
and HV
Walton et al. [37] 2013 NA Yes Faeces GCMS Processing: Within 4 h. Storage: 80°C. Quantity: 5 ml. Prepara-
tion: Nalophan bag -> 40°C for 10 min. Headspace: Yes, 500 ml.
GC-column: ZebronTM ZB-624 GC Capillary Column (20 m x
018 mm x 100mm; Phenomenex).








No Faeces GC Processing: Within 6 h. Storage: 20°C. Quantity: 10 ml. Prepara-
tion: 50°C for 10 min. Headspace: Yes, 2 cm3. GC-column:
SPB1 Capillary GC Column (L £ I.D.30m £ 025 mm, df
025mm; Supelco, Sigma Aldrich).
NA 4-fold CV,
trainingz
IBS and UC and CD
and HV
Aggio et al. [36] 2017 Rome II,
HBI, SCCAI
No Faeces GC Processing: Within 6 h. Storage: 20°C. Quantity: 1 g. Prepara-






IBS and UC and CD
and HV
Cauchi et al. [38] 2014 NA No Breath, Faeces
and urine
GCMS Collection: TD tube. Storage: NA. Quantity: 500 ml. Preparation:
Purged for 2 min -> desorption for 5 min. Headspace: NA. GC-
column: ZebronTM ZB-624, GC Capillary Column (20 m x
018 mm x 100mm; Phenomenex).
NA Bootstrapping,
trainingz
IBS and CD and UC
and HV
CD = Crohn’s disease; CV = cross validation; FAIMS = high field asymmetric waveform ion mobility spectrometry; GC = gas chromatography; HBI = HarveyBradshaw index; HV = healthy volunteer; IBD = inflammatory bowel dis-
ease; IBS = irritable bowel syndrome; MS = mass spectrometry; NA = not available or not applicable; NIST = National institute of Standards and Technology; SIFT = selected ion flow tube; SCCAI = Simple Clinical Colitis Activity
Index; SPME = solid phase microextraction; UC = ulcerative colitis.
* Methods used to identify VOCs.
y Steps undertaken to mitigate against external validation in the development of models.
























Separation of chemical components based on their
relative affinity with a capillary column. Components
elute from the GC-column with different retention
times after which they are captured, ionised, acceler-
ated, deflected and detected by the MC.
 + + + Offline +
Ion mobility spectrometry (IMS) Separation of chemical components on the basis of
differences in ion mobilities within an electric field
+    Online 
Selective ion flow tube-mass
spectrometry (SIFT-MS)
Absolute quantification of trace VOC by ionisation with
precursor/reagent ions
+ +   Online 
Electronic nose (E-nose) Array of sensors creating a smell “fingerprint”with
pattern recognition modules resembling the
olfactory system
  + + Offline +
Field asymmetric ion mobility
spectrometry (FAIMS)
Separation of chemical components on the basis of
differences in ion mobilities within an electric field
+    Online 
++: =applicable/high/long; -: =not applicable/low/short; Online: =immediate analysis of the sample; Offline: =preconcentration of samples and possibility of storing
samples for later analysis.
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CD and UC patients have frequent flares [50,51]. Therefore, VOC
analysis holds potential to monitor disease activity and assess the
effect of treatment to guide personalised medicine (supplementary
Table 3, Fig. 1c, d). A decrease of breath pentane in CD and UC
patients in remission compared to active disease was observed
[39,47]. This is not unexpected since pentane has been identified as
marker for lipid peroxidation [52], making it a non-specific inflam-
matory biomarker. After treatment of CD patients, a significant
decrease in six faecal compounds was found in two studies from theFig. 1. Individual VOCs in IBD and IBS. Compounds described in morsame research group: 3-methylbutanoic acid, butan-1-ol, butanoic
acid, ethyl butanoate, ethyl propanoate and methyl butanoate
[37,46]. A decrease in propan-1-ol in breath and faeces was described
in four articles (two by the same group) [32,37,46,47].
3.2. Discriminative models combining VOCs
3.2.1. Technology and methodological issues
Identifying compounds is of great interest to explore the underly-
ing pathological mechanisms. However, not all analytical approachese than one study are in bold. ": upregulated. #: downregulated.
6 K. Van Malderen et al. / EBioMedicine 54 (2020) 102725create a chemical identification of VOCs, like GCMS, but recognise
sensor responses to the bulk of VOCs as patterns or volatile ‘finger-
prints’, like eNoses (Tables 1 and 2). Furthermore, no single VOC was
found nor validated by multiple research groups resulting in little
clinical value to be used as stand-alone biomarker for (differential)
diagnosis. Therefore, combining VOCs in biomarker panels should
allow to create discriminative algorithms with increased sensitivity
and specificity to accurately diagnose, differentiate and monitor
patients over time. Sixteen articles described 17 algorithms based
upon breath, faeces and urine samples: 2 discriminating IBD patients
from HV, 5 discriminating CD patients from HV, 4 discriminating UC
from HV and 6 discriminating IBS from HV (Table 3). A lot of method-
ological variation was seen when sampling VOCs in the different
matrices and even within the same sample source. Breath samples
were processed between 1 and 6 h after sampling into Tedlar, Nalo-
phan of Mylar bags or onto thermal desorption columns. Although
some were stored at room temperature, one did store breath samples
at 20°C (Table 1). Finally, between 50 ml and 5 L of breath samples
were analysed. Faecal samples were processed between 1 and 6 h
after sampling and storage at 20°C or 80°C. The volume of faecal
samples ranged from 250 mg to 4 g with 2 g being the most preva-
lent. Also, some samples were homogenised of which 510 ml was
sampled. The samples were heated and VOCs captured by solid phase
microextraction (SPME) fibres. The small number of studies that ana-
lysed VOCs in the headspace of urine processed 110 ml of urine
within 26 h after storage at 80°C and heating to 38°C or 60°C.
Furthermore, most articles combined VOCs into discriminating pan-
els with the help of different regression models, two articles used an
eNose to detect a breath pattern based upon sensor changes, analysed
by pattern recognition tools like principle component analysis (PCA)
(Table 3). PCA reduces a large set of variables to a small set containing
most of the information of the large set by transforming a number of
(possibly) correlated variables into a (smaller) number of uncorrelated
variables called principal components. Although some studies reported
the individual compounds that build these discriminative models (sup-
plementary Table 4), others have not or sensor technology was used
which does not identify individual compounds but compares the sensor
responses by pattern recognition tools. Hence, using PCA and heat map
analysis, most studies clearly discriminated healthy volunteers from
patients based upon their breath pattern.
3.2.2. Inflammatory bowel disease
When discriminating CD patients from HV in breath and faeces,
accuracies ranged between 8597%, sensitivities between 6996%,
specificities between 6799% and the area under the receiver operat-
ing characteristic curves (AUCROC) between 077099 [38,41,44,53].
Discriminating UC patients from HV in breath and faeces yielded
accuracies, sensitivities, specificities and AUCROC’s ranging between
5896%, 4391%, 6294% and 054074, respectively, with lower
numbers found in faecal models [38,41,42,44]. This could be due to
the larger microbial influence in the faecal VOC samples.
3.2.3. Irritable bowel syndrome
Differentiating IBS patients from healthy volunteers by breath, fae-
ces and urine lead to accuracies, sensitivities, specificities and AUCROC’s
between respectively 4668%, 3889%, 7180% and 044092
[24,32,34,38].
3.2.4. Differential diagnosis
In contrast to the higher number of studies comparing patients to
HV, only eight models discriminated between patient populations in
order to assess the clinical utility of VOCs for differential diagnosis.
Two described the differentiation between IBD versus IBS patients
(faeces) [32,34], two between CD versus UC patients (breath) [41,44],
one between IBS versus CD patients (faeces) [32], one between IBS ver-
sus UC patients (faeces) [32], one between IBS versus coeliac diseasepatients (urine) [33] and one between IBD versus non-IBD colitis
patients (breath) [40]. The models discriminating patient groups have
a better performance than those comparing patients with HV, with
accuracies ranging between 6897%, sensitivities between 6790%,
specificities between 6290% and AUCROC’s between 070097. How-
ever, most of these models were developed in single centre studies
without independent external validation by others.
3.2.5. Monitoring inflammatory bowel disease
One study discriminated patients with active CD and CD in remis-
sion, (AUCROC: 088) [53], suggesting a potential for follow-up of
patients over time and to monitor disease activity. Nonetheless, the
VOCs used in this algorithm remained unidentified and these results
were not validated, limiting its current clinical implementation. Two
studies compared patients with active IBD (CD and UC) and IBD in
remission, in addition to comparing them to IBS patients and HV
[36,45]. PCA analysis clearly separated patients with active CD, CD in
remission and HV, but patients with active UC, UC in remission and
HV could not be differentiated [45]. The second study showed a good
separation between patients with active UC and UC in remission, but
not between pooled patients with active IBD (CD and UC) and IBD in
remission [36]. These contradictory results highlight the need for fur-
ther research evaluating active disease and disease in remission
before drawing definitive conclusions and implementation.
3.3. Microbial influence
In IBS and IBD, the microbiota plays an important role and is
therefore a major contributor in VOC analysis [17,18]. Microbial
changes influence the metabolic processes in the body (permeability,
digestion) and the microbiota itself produces numerous VOCs [54].
Hence, changes in VOC composition can be expected in these
patients, especially when studying faecal VOCs considering their
direct contact with the gut microbiota. It remains unclear whether
VOCs are produced by the microbiota or by the patient’s intrinsic
pathology. Only Smolinska et al. focused on this microbial relation-
ship in CD patients. Through PCA and canonical correlation analysis,
18 VOCs significantly correlated with 19 bacterial taxa in active dis-
ease and 17 VOCs correlated with 17 bacterial taxa in patients in
remission (supplementary Table 5). Three bacterial taxa and nine
VOCs were present in active and inactive disease [54]. This study was
the first to prove the interplay between VOCs and microbiota and
highlights the need to take the microbial composition into account in
future studies.
3.4. Personalised medicine
For IBS, there is currently no ‘one-fits-all’ treatment, making it a
cumbersome process of trial and error, which can negatively impact
patient comfort. In addition, the treatment response needs to be eval-
uated and adjusted accordingly. Therefore, predictive biomarkers to
preselect the most suitable treatment are of great interest, fulfilling
the increasing demand for personalised medicine.
Walton et al. conducted an interventional study investigating the
effect of treatment on VOC composition in faeces in patients with CD,
UC and IBS [37]. All patients received two weeks of treatment: CD
patients (n = 8) received elemental nutrition wherein proteins are
cleaved into individual amino acids, UC patients (n = 12) received
oral corticosteroids and 5-aminosalicylic acid derivatives with no
specific diet, and IBS patients (n = 4) were treated by an exclusion
diet. Before treatment, there was a significant increase in the faecal
VOC concentrations of ester and alcohol derivates of short chain fatty
acids (SCFAs) and indole in CD patients compared to the other groups.
In patients with UC and IBS, indole and phenol levels tended to be
higher compared to HV. After treatment, faecal VOC concentrations
normalised to those of HV [37].
Table 3
VOC models.





1 2014 [34] IBD vs HV NA IBD 101 HV 46 Acc: Mean 79%; IBD 78%; HV 80%
2 2016 [41] IBD vs HV NA IBD 54 HV 22 Sens: 74%, Spec: 75%, AUC: 082
Crohn’s disease
3 2015 [53] CD R vs HV 6 CD 191 CDR NA HV 110 Acc: 923%, Sens: 96%, Spec: 99%, AUC: 099
4 2015 [53] CD A vs HV 7 CD 191 CDA NA HV 110 Acc: 973%, Sens: 96%, Spec: 97%, AUC: 098
5 2015 [44] CD vs HV 6 CD 18 HV 18 OSC-PLS-DA: Clear separation groups. Sens: 944%, Spec:
944%, AUC: 0864
6 2016 [41] CD vs HV NA CD 25 HV 22 Sens: 69%, Spec: 67%, AUC: 077
7 2014 [38] Faeces: CD vs HV NA CD 24 HV 20 Acc: 85%, Sens: 93%, Spec: 78%, AUC: 097
Ulcerative colitis
8 2007 [42] UC vs HV 32 UC 18 HV 30 DS: Clear separation groups. Acc: 100 (96)%
9 2015 [44] UC vs HV 6 UC 20 HV 18 Sens: 905%, Spec: 944%, AUC: 0742
10 2016 [41] UC vs HV NA UC 29 HV 22 Sens: 61%, Spec: 62%, AUC: 070
11 2014 [38] Faeces: UC vs HV NA UC 19 HV 20 Acc: 58%, Sens: 43%, Spec: 69%, AUC: 054
Irritable bowel syndrome
12 2013 [32] IBS vs HV 49 IBS 30 HV 109 Acc: IBS 70 (68)%; HV 95 (94)%, Sens: 90 (82)%, Spec: 80 (78)%,
AUC: 094 (092)
13 2014 [34] IBS vs HV NA IBS 34 HV 46 Acc: Mean 54%; IBS 46%; HV 58%
14 2016 [24] IBS vs HV 16 IBS 170 HV 153 PCA: Clear separation groups. Acc: Positive 84%; Negative:
81.5%, Sens: 894%, Spec: 733%, AUC: 083
15 2014 [38] Breath: IBS vs HV NA IBS 28 HV 20 Acc: 58%, Sens: 41%, Spec: 72%, AUC: 044
16 2014 [38] Faeces: IBS vs HV NA IBS 28 HV 20 Acc: 61%, Sens: 51%, Spec: 71%, AUC: 063
17 2014 [38] Urine: IBS vs HV NA IBS 28 HV 20 Acc: 64%, Sens: 38%, Spec: 80%, AUC: 053
Active disease versus disease in remission
Crohn's disease
18 2015 [53] CD A vs CD R 10 CD 191 CDA NA CDR NA Acc: CD A 815%; CD R 864%, Sens: 81%, Spec: 80%, AUC: 088
Disease versus disease
Inflammatory bowel disease and irritable bowel syndrome
19 2013 [32] IBS vs active IBD 60 IBS 30 IBD 110 Acc: IBS 80 (70)%; IBD 96 (95)%, Sens: 96 (80)%, Spec: 80 (62)%,
AUC: 098 (076)
20 2014 [34] IBS vs IBD NA IBS 34 IBD 101 Acc: Mean 76%; IBS 68%; IBD 82%, Sens: 76%, Spec: 88%
Crohn’s disease and ulcerative colitis
21 2015 [44] CD vs UC 6 CD 18 UC 20 Sens: 889%, Spec: 900%, AUC: 0828
22 2016 [41] UC vs CD NA CD 25 UC 29 Sens: 67%, Spec: 67%, AUC: 070
Irritable bowel syndrome and Crohn’s disease
23 2013 [32] IBS vs CD 44 IBS 30 CD 62 Acc: IBS 80 (80)%; CD 100 (97)%, Sens: 94 (90)%, Spec: 82
(80)%, AUC: 097 (093)
Irritable bowel syndrome and ulcerative colitis
24 2013 [32] IBS vs UC 44 IBS 30 UC 48 Acc: IBS 87 (83)%; UC 94 (92)%, Sens: 96 (90)%, Spec: 80 (80)%,
AUC: 096 (088)
Irritable bowel syndrome and coeliac disease
25 2014 [33] IBS vs coeliac disease NA IBS 20 Coeliac 27 Heat map: Clear separation groups. Sens: 85%, Spec: 85%,
AUC: 091
Inflammatory bowel disease and non-inflammatory bowel disease
26 2016 [40] IBD vs non-IBD 4 IBD 35 Non-IBD 6 AUC: 081
Combinations
Crohn’s disease and ulcerative colitis and healthy
27 2011 [65] CD vs UC vs HV NA CD 15 UC 4 HV 8 PCA: Clear separation groups
28 2013 [66] CD vs UC vs HV NA CD 24 UC 24 HV 14 PCA: Clear separation groups. Acc: >75%
(continued)
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Table 3 (Continued)
ID Year Article Aim Number of
compounds
Study population Result
29 2016 [45] CD vs UC vs HV NA CD 117 UC 100 HV 109 PCA: Clear separation CD A, CD R and HV; Clear separation
ileal and colon CD; Unclear separation UC A, UC R and HV
Crohn’s disease and ulcerative colitis and irritable bowel syndrome and healthy
30 2017 [36] IBS vs CD vs UC vs HV NA IBS 28 CD 36 UC 49 HV 41 PCA: Clear separation CD A and IBS; Clear separation UC A and
UC R; Unclear separation IBD A and IBD R Acc: Ranging
between 75% and 100%y, Sens: NA, y Spec: NA, y AUC: NA, y
31 2014 [38] Faeces: CD vs HV and UC and IBS NA IBS 28 CD 24 UC 19 HV 20 Acc: 79%, Sens: 68%, Spec: 83% AUC: 065
32 2014 [38] Urine: CD vs HV and UC and IBS NA IBS 28 CD 24 UC 19 HV 20 Acc: 72%, Sens: 48%, Spec: 81%, AUC: 059
Other
33 2015 [53] CD A vs CD R vs HV 17 CD 191 CDA NA CDR NA HV 110 PCA: Clear separation groups. Acc: 867%
34 2017 [67] UC A vs UC R vs non-IBD colitis 11 UC 76 UCA NA UCR NA Non-IBD 22 PCA: Clear separation groups. Sens: 92%, Spec: 77%, AUC: 094
Interventional
Irritable bowel syndrome
35 2017 [35] Low FODMAP baseline model 15 Response 35 Non-response 9 PCA: Clear separation groups. Acc: treat 97%; plac 409%, Sens:
treat 100%; plac 625%, Spec: treat 88%; plac 286%
36 2017 [35] Probiotic baseline model 10 Response 29 Non-response 16 PCA: Clear separation groups. Acc: treat 89%; plac 455%, Sens:
treat 93%; plac 75%, Spec: treat 82%; plac 286%
37 2017 [35] Low FODMAP end treatment model 9 Response 30 Non-response 9 PCA: Clear separation groups. Acc: 96%, Sens: 100%, Spec: 82%
38 2017 [35] Probiotic end of treatment model 11 Response 29 Non-response 16 PCA: Clear separation groups. Acc: 91%, Sens: 92%, Spec: 90%
A = active disease; CD = Crohn’s disease; CV = cross validation; DS = discriminant score; HV = healthy volunteer; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome;
NA = not available; OSC-PLS-DA = partial least squares discriminant analysis with orthogonal signal correction; PCA = principal component analysis; R = disease in remission;
UC = ulcerative colitis.
Results are shown as: visual (PCA, heat map, OSC-PLS-DA, DS); Acc = accuracy% (after CV); Sens = sensitivity% (after CV); Spec = specificity% (after CV); AUC = area under the curve
(after CV); treat = treatment; plac = placebo.
yThis article has elaborate tables which are not included in this paper. After double cross-validation, the most clinically important findings were the accuracy of CD-A versus IBS
(87%), and IBS versus HV (78%).
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same group evaluated the effect of enteral feeding in CD patients
(n = 17) and HV (n = 7) [46]. In HV, one week of enteral feeding
increased indole and phenol levels in breath together with a change in
stool colour and the induction of halitosis. In CD patients, enteral feed-
ing improved symptoms, decreased c-reactive protein (CRP) and
decreased faecal concentrations of SCFAs, methyl and ethyl esters of
these fatty acids, propan-1-ol and 1-butanol [46].
Rossi et al. randomised IBS patients to a low-FODMAP diet versus
sham-diet and a probiotic versus placebo diet for four weeks [35].
Faecal VOCs were analysed at baseline and after treatment by an
Odoreader, which has a GC front end and a gas sensor detector and
detects patterns. VOC models to predict treatment response at base-
line resulted in a high accuracy (low-FODMAP model: 97% and probi-
otic model: 89%) for the treatment groups. However, when applying
the same models in the control groups (sham/placebo), a low accu-
racy was achieved (low-FODMAP model: 409% and probiotic model:
455%) (Table 3). This implies that these models are specific for the
response to low-FODMAP and/or probiotic rather than for response
to therapy in general, and emphasises the potential use of VOCs as
non-invasive predictive markers to optimise personal treatment [35].3.5. Metabolic pathways and VOCs
Table 4 describes only those compounds mentioned in two or more
studies. Most of these individual compounds described in this review
are found to be endogenous or exogenously present in food or pro-
duced by the microbiota. The endogenous compounds play a role in
several metabolic pathways such as lipid, butanoate, ethanol, sulphur,
propanoate and ketone metabolism and in the biosynthesis of tropane,
piperidine, pyridine alkaloid, and terpenoid backbones (Table 1).
A substantial amount of the discriminative compounds are SCFAs
and part of the butanoate, propanoate, and acetate metabolism. SCFAsare the main metabolic products of anaerobic bacterial fermentation,
serving as fuel for intestinal epithelial cells but also modulating elec-
trolyte and water absorption. More importantly, they have anti-
inflammatory properties and mediate the effect of the microbiota on
the intestinal immune function [55,56]. A second compound appearing
in biomarker panels is indole. It is formed by bacterial metabolism of L-
tryptophan and has anti-inflammatory properties, again stressing the
importance of the microbial influence on VOCs [57].
It is currently impossible to identify the detected compounds as
originating from metabolic pathways and/or from digestion of food
or medication. Moreover, all these pathways are in continuous inter-
action with inflammatory processes. This close synergy might explain
the discrepant findings in the different studies and stresses the need
to clarify and explore the VOC metabolism and distribution in differ-
ent body matrices. IBS is a very variable condition compared to IBD
which corresponds to the inconsistent findings of VOCs in IBS
patients. It appears that most of the VOCs detected in IBD patients
are related to inflammation rather than being disease specific. This
underlines the need for future studies to combine VOCs into panels
to increase the specificity for discrimination.4. Strengths, limitations and future perspectives
Promising VOCs for (differential) diagnosis include propan-1-ol in
breath and faeces, to differentiate CD patients from HV and IBS
patients. Pentane in breath differentiated patients with CD and UC
from HV. Above of this, 1-methyl-4-propan-2-ylcyclohexa-1,4-diene
was only detected in IBS patients, making it a promising biomarker
discriminating IBS from HV. Diagnosis of IBS is currently based on the
Rome IV criteria, with exclusion of organic disease. However, these
criteria are not specific, emphasising the need to develop a specific
diagnostic test for IBS. Using VOCs for disease monitoring demon-
strated a decrease of breath pentane levels when patients with CD or
Table 4
Metabolic pathways.
Compound CAS numbery Source Concentration Disease Pathway Origin Articles
2-methylbuta-1,3-diene 78795 Breath #" CD Terpenoid backbone biosynthe-
sis. Biosynthesis of terpenoids,
steroids, secondary
metabolites
Endogenous, Plant, Tobacco [47,53]
3-methylbutanoic acid 503742 Faeces " CD Biosynthesis of alkaloid and sec-
ondary metabolites. Protein
digestion and absorption
Endogenous, Plant, Animal [37,46]
6-methylheptan-2-one 928687 Faeces " CD Synthesis and degradation of
ketone bodies. Cholesterol
oxidation
Endogenous, Plant, Animal [32,45]






Butanoic acid 107926 Faeces " CD Butanoate metabolism. Meta-
bolic pathways. Carbohydrate





Ethyl butanoate 105544 Faeces " CD Lipid metabolism Endogenous, Plant, Animal [37,46]
Ethyl propanoate 105373 Faeces " CD Ethanol metabolism Endogenous, Plant [37,46]
Heptanal 111717 Faeces " CD Lipid metabolism Endogenous, Plant, Animal [32,45]
Methyl butanoate 623427 Faeces " CD Lipid metabolism Endogenous, Plant, Animal [37,46]
Methylsulphanylmethane 75183 Breath Faeces "# CD Sulphur metabolism Endogenous, Plant, Bacteria [44,45]
Pentane 109660 Breath Faeces "# CD, UC Lipid metabolism Endogenous, Plant [47,48]
Piperidin-2-one 675207 Faeces " CD Tropane, piperidine and pyridine
alkaloid biosynthesis
Endogenous [32,45]
Propan-1-ol 71238 Breath Faeces " CD Propanoate metabolism Endogenous, Plant, Animal,
Bacteria, Fungi
[32,37,46,47]
















99854 Breath Faeces " IBS NA Endogenous, Plant [24,32]
y CAS numbers are unique numerical identifiers assigned by the Chemical Abstracts Service.
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with a decrease in metabolites of microbial SCFAs in faeces, suggest-
ing a correlation with microbial changes induced by treatment. How-
ever, these individual VOCs have limited specificity. They are generally
related to inflammation and can also be altered in other diseases. For
example, 1-propanol has been previously detected in coeliac disease
[58,59] and 1-methyl-4-propan-2-ylcyclohexa-1,4-diene in colorectal
cancer [60]. Pentane on the other hand has not only been detected in
CD and UC but also in asthma, heart failure and non-alcoholic fatty
liver disease. Breath pentane levels are an index for lipid peroxidation
and therefore could serve as marker for general inflammation, ferrop-
tosis or apoptosis. This emphasises the need to combine these VOCs in
discriminative models and with other clinical/biochemical data to
increase disease specificity, especially for monitoring. Furthermore,
there is a need to include appropriate controls. A lot of the studies
included in this review compared patients with HV. However, it would
clinically be more beneficial to focus on comparing symptomatic
groups of patients. Future studies should therefore focus on comparing
these symptomatic groups.
Furthermore, VOC models differentiating CD patients from HV
seem to be the most successful. In contrast, models discriminating
IBS patients from HV showed the lowest discriminative capacity,
which could be explained by the heterogeneity of the population.
There is a wide variation of VOC data within the IBS population with
some being clearly aberrant and others resembling HV. This empha-
sises the importance of studying separate IBS subtypes in the future
to increase homogeneity. Subtyping patients is not only crucial in IBS,
but also in IBD, since the underlying pathogenesis of CD and UC is
remarkably different. Ideally, patients with active and remissivedisease should also be differentiated since first results suggest a nor-
malisation of VOC profiles in remission. Hence, pooling of these
patients could cause a loss of crucial information. Most of the
included studies are pilot studies having small subgroup sample sizes
(supplementary Table 2). Since more VOCs are detected in breath
than the number of patients included in the studies, this can lead to
an overfitting of data resulting in overoptimistic results. It is there-
fore important for future studies to take this into account and use
dimension reduction statistics and to include a sufficient number of
participants in each subgroup.
The three interventional studies demonstrated the added value of
VOC analysis in assessing treatment response, and in predicting
response to a specific intervention and, therefore, in selecting the
best treatment option. This indicates the need to develop multiple
volatile models which are individually linked to a specific interven-
tion in order to be able to accurately give the right and most effective
treatment to individual patients. When looking at the VOCs in those
models, limited overlap in the different models is seen (supplemen-
tary Table 4). This reflects the heterogeneity between studies and
stresses the need for standardised sampling as advised by current
guidelines in breath analysis [61].
By studying VOCs induced by microbiota, intrinsic VOCs originat-
ing from human pathogenic metabolism can be deducted. VOCs in
this review were mostly derived from pathways with a strong syn-
ergy with inflammatory processes. This knowledge can be imple-
mented in in vitro or in vivo experiments and in the development of
novel germ-free mouse or rat models colonised with human micro-
biota. This will further advance IBS and IBD research by allowing vali-
dation of results. Additionally, it would be interesting to know the
Fig. 2. The potential of VOC analysis in the management of IBS and IBD. VOCs can originate from metabolic processes, both physiologic and pathophysiologic (inflammation or oxi-
dative stress), and by the microbiota. Hence, a flare up or change in micobial composition can be reflected in VOC changes. However, this also stresses the potential of confounding
external factors like drugs and diet that need to be accounted for. VOCs are liberated by the gastrointestinal cells and can be excreted in faeces, but are also transported through the
bloodstream and can hence be detected in breath and urine, offering non-invasive alternatives for future disease management.




1. Thorough and scientifically sound description of the patient population
a. Healthy volunteers and use of appropriate control groups
Despite good discriminative models between patients and HV, little is known about the VOC composition in
HV and their natural evolution over time, the healthy human volatilome. Therefore, longitudinal prospec-
tive studies analysing VOCs in HV and patients will help determining a baseline healthy individual volati-
lome and map reproducibility.
b. Inclusion of cases that can interfere with differential diagnosis
To be able to accurately differentiate IBS and IBD, not only from each other but also from other gastrointes-
tinal disorders, research should ideally include a broader range of gastrointestinal disorders in a case-
control design to be able to compare results and to optimise specificity.
c. Dividing patients in disease subtypes
IBS and IBD patients are heterogeneous populations. Pooling data, therefore, is not advocated since it can
distort results and important differences can be missed. IBS should ideally be classified according to the
Rome IV criteria: diarrhoea, constipation, mixed and unspecified. The underlying pathophysiology is pre-
sumably different and different VOC patterns are thus to be expected. IBD patients should also be divided
in CD and UC, and further subtyping in active disease and disease in remission could reveal interesting
discriminatory characteristics. A proper sample size calculation should address the total number of
patients to reveal subgroup characteristics.
2. Standardisation of the used methodology
The quality of the research included in this review, evaluated with the AXIS tool, is reasonable, but there is
room for improvement in order to pinpoint relevant specific VOCs. Hence, to be able to compare results
and cluster data, it is paramount for future research to perform proper sample size calculations, and
achieve a high level of quality and standardisation, in composition of the research population, used
research methods and sampling conditions. The European Respiratory Society has published guidelines
concerning standardisation of breath analysis and future research should take this into account [61]. Dif-
ferences in used technologies should be taken into account when comparing data. Interventional trials
should ideally be organised as randomised placebo-controlled trials or cross-over trials.
3. Description of chemical denomination of the detected
compounds allowing comparison between studies
Compounds should be described with the help of standardised international systems like the International
union of pure and applied chemistry (IUPAC) nomenclature and numbers of the Chemical Abstracts Ser-
vice (CAS). Compounds should ideally be verified using external standards and its concentration should
be mentioned in studies for comparison.
4. Use of validation cohorts
The different models show very limited similarities, making comparison difficult. We stress the need for
studies to split up patients and design models in a test set, and externally validating the discriminative
models in independent patient validation groups in order to assess clinical utility. When validating
results in different research facilities one should try to use the same technology and setup of the equip-
ment. Another argument to promote validation is the limited sample size of some studies, since this could
lead to overfitting of the data, leading to overoptimistic results.
5. Unravel the metabolic pathways involved
VOCs are formed by metabolic processes and influence other pathways. Analysis of VOCs and their underly-
ing metabolic pathways could help explain the pathophysiological mechanisms causing IBS and IBD.
Pathways and VOCs of interest could then be further analysed in in vivomodels and animal research,
potentially leading to detection and development of novel therapeutic targets. Short chain fatty acids are
the group of compounds that stand out the most across all studies. Their role in inflammatory disorders is
well documented so their presence in VOC analysis is not unexpected. A VOC compound of high interest
is propan-1-ol, a part of the propanoate metabolism. It is mentioned in multiple articles looking into CD, it
is found to be increased in CD patients compared to HV and IBS patients and, more importantly, it
decreases after effective treatment, making propan-1-ol a compound with great potential as a discrimi-
native VOC biomarker and also in predicting treatment effects of CD patients.
6. Match data of breath, faeces and urine analyses
Future studies should compare the VOC composition in breath, urine and faeces of the same patient which
could give some insights into metabolic processes playing a role in disease and to elucidate the VOC
metabolism from gut to breath.
7. Description of the environmental context and
confounding factors
a. Environmental context
The surrounding air, called exposome, can majorly influence VOC composition. Therefore, it is crucial to
take background samples and correct for possible external influences. The authors should ideally describe
in detail how they corrected for differences in sample collection, sample handling, storage conditions and
sample preparation.
b. Confounding factors
Patient factors can also influence results of VOC analysis, for example diet, exercise, and drugs. For instance,
the FODMAP-diet influences the microbiota [17,68] and is frequently used to treat IBS and IBD patients.
FODMAP carbohydrates are poorly digested and, as a consequence, are fermented by the colon microbiota
leading to increased gas production and an osmotic effect in the bowel [17]. This indicates that the thera-
peutic effect of dietary interventions is heavily dependent on the composition of the microbiota of the
patient [68]. For example, FODMAPs cause a decrease in Clostridium coccoides, Akkermansia muciniphila,
Mycoplasma hominis, Bifidobacterium and Actinobacteria; and an increase in Ruminococcus torques [68].
The microbiota on the other hand produce metabolites through digestion of nutrients, which can have a
direct or indirect effect on symptoms in IBS and IBD. Possible confounding factors should, therefore, be
registered and taken into account when analysing data.
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development in disease states. Comparing profiles of active and
remissive disease will give insight into the mechanisms of different
treatment options. Correlation of VOC profiles with the patient’s
microbiota will shed light on the role of the microbiota in symptom
development and the interaction with drugs and diet. The large inter-
individual variability in microbial composition, even in HV, compli-
cates defining baseline values and may impede the development ofdiagnostic tests. Therefore, more research looking into this interplay
between VOCs and the microbiota in HV and patients is imperative.
Overall, current research is very diverse and heterogeneous, with
different in- and exclusion criteria, sampling techniques, and analyti-
cal methods (Table 1). Several studies discussed the influence of sam-
ple handling, transportation, storage conditions and preparation on
VOC composition [62,63]. Furthermore, different technologies will
not necessarily provide the same results and even using the same
12 K. Van Malderen et al. / EBioMedicine 54 (2020) 102725equipment is no guarantee as the set-up can differ (Table 1). Most
articles used breath and faeces as VOC matrix, with only four articles
studying urine. Further research into the correlation between breath,
faecal and urinary VOCs could give insight into the metabolic VOC
processes (Fig. 2). Also, environmental confounding should be taken
into account. Characteristics such as race, cultural surroundings, diet,
drugs and lifestyle all have an impact on microbial composition and
therefore VOCs [64]. For example, 1-methyl-4-propan-2-ylcyclo-
hexa-1,4-diene in IBS patients can originate from exogenous (diet)
and endogenous (stabilisation of cell membrane and cell signalling)
sources. Recording the diet could shed light on the biochemical origin
of this VOC. It is important to identify all confounding factors to gain
better insight in their impact on VOCs and match patients and con-
trols [22,62]. Therefore, we recommend taking the abovementioned
confounders into account when designing future volatomic trials
(Table 5).5. Conclusion
Volatomics in the diagnosis and follow-up of IBD and IBS patients
show enormous potential. Promising diagnostic VOCs of interest are
propan-1-ol in CD and 1-methyl-4-propan-2-ylcyclohexa-1,4-diene
in IBS, in breath and faeces. However, volatomics have not yet led to
a clinically useful and validated biomarker tool due to technical and
quality issues. Next to this, VOCs also show clear potential for the
non-invasive assessment of treatment efficacy and personalised
medicine. Further development of our knowledge, uncovering under-
lying pathophysiological mechanisms and novel therapeutic targets,
could have a major impact on patient and health care costs, since
diagnosis and follow-up are often bothersome and expensive. We
encourage future research to focus upon these issues and perform
adequately designed, qualitative studies taking environmental factors
and guidelines into account to move forward in the development of a
non-invasive test for IBS and IBD. We believe VOC biomarkers will be
most useful combined with other (clinical) parameters, particularly
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